Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8883783 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(2 years from now) | |
US7820657 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Sep, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8129374 | DAIICHI SANKYO INC | Method of using imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(2 years from now) | |
US9585892 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(2 years from now) | |
US8557810 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(2 years from now) | |
US7968543 | DAIICHI SANKYO INC | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
Aug, 2029
(5 years from now) | |
US8865710 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
Aug, 2029
(5 years from now) | |
US8836218 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Mar, 2030
(5 years from now) | |
US9555040 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
May, 2030
(6 years from now) | |
US8357690 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Feb, 2031
(6 years from now) | |
US9675549 | DAIICHI SANKYO INC | Tablet containing composite with cyclodextrin |
Sep, 2033
(9 years from now) |
Vanflyta is owned by Daiichi Sankyo Inc.
Vanflyta contains Quizartinib Dihydrochloride.
Vanflyta has a total of 11 drug patents out of which 0 drug patents have expired.
Vanflyta was authorised for market use on 20 July, 2023.
Vanflyta is available in tablet;oral dosage forms.
Vanflyta can be used as combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagnosed flt3-itd positive acute myeloid leukemia.
Drug patent challenges can be filed against Vanflyta from 21 July, 2027.
The generics of Vanflyta are possible to be released after 30 September, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
Dosage: TABLET;ORAL